Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7QVJ

ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH COMPOUND 29

Summary for 7QVJ
Entry DOI10.2210/pdb7qvj/pdb
DescriptorEstrogen receptor, 2,2-bis(fluoranyl)-3-[(1~{R},3~{R})-1-[6-fluoranyl-3-[2-(3-fluoranylpropylamino)ethoxy]-2-methyl-phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]propan-1-ol (3 entities in total)
Functional Keywordsligand-binding domain of oestrogen nuclear hormone receptor, transcription
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight58326.17
Authors
Breed, J. (deposition date: 2022-01-21, release date: 2023-02-01, Last modification date: 2024-02-07)
Primary citationScott, J.S.,Stead, D.,Barlaam, B.,Breed, J.,Carbajo, R.J.,Chiarparin, E.,Cureton, N.,Davey, P.R.J.,Fisher, D.I.,Gangl, E.T.,Grebe, T.,Greenwood, R.D.,Hande, S.,Hatoum-Mokdad, H.,Hughes, S.J.,Hunt, T.A.,Johnson, T.,Kavanagh, S.L.,Klinowska, T.C.M.,Larner, C.J.B.,Lawson, M.,Lister, A.S.,Longmire, D.,Marden, S.,McGuire, T.M.,McMillan, C.,McMurray, L.,Morrow, C.J.,Nissink, J.W.M.,Moss, T.A.,O'Donovan, D.H.,Polanski, R.,Stokes, S.,Thakur, K.,Trueman, D.,Truman, C.,Tucker, M.J.,Wang, H.,Whalley, N.,Wu, D.,Wu, Y.,Yang, B.,Yang, W.
Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.
J.Med.Chem., 66:2918-2945, 2023
Cited by
PubMed Abstract: Herein, we report the optimization of a meta-substituted series of selective estrogen receptor degrader (SERD) antagonists for the treatment of ER+ breast cancer. Structure-based design together with the use of modeling and NMR to favor the bioactive conformation led to a highly potent series of basic SERDs with promising physicochemical properties. Issues with hERG activity resulted in a strategy of zwitterion formation and ultimately in the identification of . This compound was shown to be a highly potent SERD capable of effectively degrading ERα in both MCF-7 and CAMA-1 cell lines. The low lipophilicity and zwitterionic nature led to a SERD with a clean secondary pharmacology profile and no hERG activity. Favorable physicochemical properties resulted in good oral bioavailability in preclinical species and potent activity in a mouse xenograft model.
PubMed: 36727211
DOI: 10.1021/acs.jmedchem.2c01964
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.68 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon